100 related articles for article (PubMed ID: 12466974)
1. Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors.
Payton M; Scully S; Chung G; Coats S
Oncogene; 2002 Dec; 21(55):8529-34. PubMed ID: 12466974
[TBL] [Abstract][Full Text] [Related]
2. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D2 expression in familial and sporadic breast cancer.
Fischer H; Chen J; Skoog L; Lindblom A
Oncol Rep; 2002; 9(6):1157-61. PubMed ID: 12375011
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.
Weroha SJ; Li SA; Tawfik O; Li JJ
Carcinogenesis; 2006 Mar; 27(3):491-8. PubMed ID: 16311245
[TBL] [Abstract][Full Text] [Related]
5. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.
Gery S; Tanosaki S; Bose S; Bose N; Vadgama J; Koeffler HP
Clin Cancer Res; 2005 May; 11(9):3184-90. PubMed ID: 15867211
[TBL] [Abstract][Full Text] [Related]
7. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
Liu Y; Lu C; Shen Q; Munoz-Medellin D; Kim H; Brown PH
Oncogene; 2004 Oct; 23(50):8238-46. PubMed ID: 15378019
[TBL] [Abstract][Full Text] [Related]
8. Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype.
Libertini SJ; Robinson BS; Dhillon NK; Glick D; George M; Dandekar S; Gregg JP; Sawai E; Mudryj M
Cancer Res; 2005 Dec; 65(23):10700-8. PubMed ID: 16322214
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer.
Maddison LA; Huss WJ; Barrios RM; Greenberg NM
Prostate; 2004 Mar; 58(4):335-44. PubMed ID: 14968434
[TBL] [Abstract][Full Text] [Related]
10. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
11. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
12. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition.
Madi L; Ochaion A; Rath-Wolfson L; Bar-Yehuda S; Erlanger A; Ohana G; Harish A; Merimski O; Barer F; Fishman P
Clin Cancer Res; 2004 Jul; 10(13):4472-9. PubMed ID: 15240539
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Kobatake T; Yano M; Toyooka S; Tsukuda K; Dote H; Kikuchi T; Toyota M; Ouchida M; Aoe M; Date H; Pass HI; Doihara H; Shimizu N
Oncol Rep; 2004 Nov; 12(5):1087-92. PubMed ID: 15492797
[TBL] [Abstract][Full Text] [Related]
14. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome.
Bondi J; Husdal A; Bukholm G; Nesland JM; Bakka A; Bukholm IR
J Clin Pathol; 2005 May; 58(5):509-14. PubMed ID: 15858123
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
16. Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer.
Spruck C; Sun D; Fiegl H; Marth C; Mueller-Holzner E; Goebel G; Widschwendter M; Reed SI
Cancer Res; 2006 Jul; 66(14):7355-60. PubMed ID: 16849587
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues.
Hines WC; Fajardo AM; Joste NE; Bisoffi M; Griffith JK
Mol Cancer Res; 2005 Sep; 3(9):503-9. PubMed ID: 16179497
[TBL] [Abstract][Full Text] [Related]
18. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of cyclin D1 and cyclin E in 1,2-dimethylhydrazine dihydrochloride-induced rat colon carcinogenesis.
Hur K; Kim JR; Yoon BI; Lee JK; Choi JH; Oh GT; Kim DY
J Vet Sci; 2000 Dec; 1(2):121-6. PubMed ID: 14614307
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Irahara N; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2006 Nov; 243(1):23-31. PubMed ID: 16556483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
